Cannabis-based medicinal MS drug for £7,500 per year!

Spasticity is a feature of altered skeletal muscle performance in muscle tone involving hypertonia; it is also referred to as an unusual "tightness", stiffness, and/or "pull" of muscles.
Clinically spasticity is defined as velocity dependent resistance to stretch, where a lack of inhibition results in excessive contraction of the muscles.
The clinical underpinnings of spasticity in multiple sclerosis could be from poor oxygenation. THIS HOWEVER IS A HYPOTHESIS AND AWAITS VERIFICATION.

Cannabis-based medicinal MS drug for £7,500 per year!

Postby themsforum.org » Thu, 25 Oct 2012, 7:02 pm

"Background: Spasticity is common in patients with multiple sclerosis (MS) and is a major contributor to disability. Sativex®, an oromucosal spray containing cannabis-based medicinal products, has been found to be effective in reducing spasticity symptoms. (We do not know where this evidence is. Perhaps someone can fill us on this)
Objective: Our objective was to estimate the cost effectiveness of Sativex® plus oral anti-spasticity medicines compared with the current standard treatment for moderate or severe spasticity in MS in the UK.
Methods: A Markov model was used to assess the costs and benefits of Sativex® plus oral anti-spasticity medicines or current standard treatment based on their effects on the quality of life of patients. The main outcome was the incremental cost-effectiveness ratio (ICER) in terms of costs per additional QALY gained over 5 years of treatment. One-way, multi-way and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties on the findings.
Results: In the base case, Sativex® plus oral anti-spasticity medicines resulted in incremental costs of £7600 and a QALY gain of 0.15 per person over 5 years (ICER = £49 300 per QALY) [year 2009 data for costs]. Findings were sensitive to the costs of Sativex® (price and dose) and differences in utilities between responders and non-responders.
Conclusions: Using a willingness-to-pay threshold of £30 000 per QALY, Sativex® appears unlikely to be considered cost effective by UK funders of healthcare for spasticity in MS."
themsforum.org
Site Admin
 
Posts: 164
Joined: Fri, 28 Sep 2012, 9:08 pm

Return to Spasticity in 'MS' patients

cron